Home › Funds › Paradigm Biocapital Advisors LP › SYRE

Paradigm Biocapital Advisors LP position in SYRE

SPYRE THERAPEUTICS INC · Health Care

Paradigm Biocapital Advisors LP reported holding 4,457,450 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$396.8M, representing 7.89% of its reported portfolio and ranking #4 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed SYRE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)4.46M sh
Reported value held$396.85M
Portfolio Weight7.89%
First reportedQ3 2024
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's SYRE position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in SYRE in Q3 2024 at 1,267,581 shares (US$37.3M). The position peaked in Q3 2026 at 4,457,450 shares, worth US$396.8M. Across 9 filings, Paradigm Biocapital Advisors LP increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 4,457,450 shares valued at US$396.8M — an increase of 616,672 shares quarter over quarter.. Notable position changes include a 39% increase in Q1 2025 (shares fell 7% over the following quarter), a 33% increase in Q1 2026 (shares rose 76% over the following quarter), a 96% increase in Q2 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 1.27M $37.28M New
Q4 2024 1.53M $35.55M Add
Q1 2025 2.13M $34.32M Add
Q2 2025 1.87M $28.00M Reduce
Q3 2025 1.47M $24.59M Reduce
Q4 2025 1.47M $48.07M Hold
Q1 2026 1.96M $98.72M Add
Q2 2026 3.84M $340.98M Add
Q3 2026 4.46M $396.85M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$328.7M), Venrock Adviser, LLC (US$265.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held SYRE?

Paradigm Biocapital Advisors LP has disclosed SYRE holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Paradigm Biocapital Advisors LP's current position in SYRE?

As of Q3 2026, Paradigm Biocapital Advisors LP holds 4.46M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $396.85M, representing 7.89% of its reported portfolio and ranking #4.

Has Paradigm Biocapital Advisors LP been buying or selling SYRE?

In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP increased its position in SYRE. The position peaked in Q3 2026 at 4.46M shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Venrock Adviser, LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.